Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus with IL-2 receptor antagonist, corticosteroids, and two tacrolimus exposure levels in de novo kidney transplant recipients
2005-001714-41Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2005
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus and tacrolimus in Kidney allograft status (RTx) (2 arms), sponsored by Novartis. Primary endpoints: Renal function at 12 months post-transplant and Calculated glomerular filtration rate by MDRD at 12 months. Started Dec 2005; status: completed.
02
Drugs
everolimustacrolimus
03
Conditions
Kidney allograft status (RTx)
Beyond the preview
Go deeper on 2005-001714-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001714-41.